GINMU >

Browsing by Author Akahane, Takemi

Issue Date	Title	Author(s)
Apr-2023	A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation	Suzuki, Junya; Kaji, Kosuke; Nishimura, Norihisa; Kubo, Takahiro; Tomooka, Fumimasa; Shibamoto, Akihiko; Iwai, Satoshi; Tsuji, Yuki; Fujinaga, Yukihisa; Kitagawa, Koh; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
Dec-2021	Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats	Takeda, Soichi; Kaji, Kosuke; Nishimura, Norihisa; Enomoto, Masahide; Fujimoto, Yuki; Murata, Koji; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
14-Oct-2020	Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.	Kitagawa, Koh; Moriya, Kei; Kaji, Kosuke; Saikawa, Soichiro; Sato, Shinya; Nishimura, Norihisa; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
19-Jun-2020	Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis.	Tsuji, Yuki; Kaji, Kosuke; Kitade, Mitsuteru; Kaya, Daisuke; Kitagawa, Koh; Ozutsumi, Takahiro; Fujinaga, Yukihisa; Takaya, Hiroaki; Kawaratani, Hideto; Namisaki, Tadashi; Moriya, Kei; Akahane, Takemi; Yoshiji, Hitoshi
Dec-2019	Combination of L-Carnitine and Angiotensin-II type 1 Receptor Blocker has Beneficial Effects on Hepatic Fibrosis in a Non-Alcoholic Steatohepatitis Rat Model.	Kubo, Takuya; Kawaratani, Hideto; Sawada, Yasuhiko; Fujinaga, Yukihisa; Ozutsumi, Takahiro; Kaya, Daisuke; Tsuji, Yuki; Nakanishi, Keisuke; Furukawa, Masanori; Kitagawa, Kou; Saikawa, Soichiro; Sato, Shinya; Takaya, Hiroaki; Kaji, Kosuke; Shimozato, Naotaka; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
21-Mar-2020	Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.	Ozutsumi, Takahiro; Namisaki, Tadashi; Shimozato, Naotaka; Kaji, Kosuke; Tsuji, Yuki; Kaya, Daisuke; Fujinaga, Yukihisa; Furukawa, Masanori; Nakanishi, Keisuke; Sato, Shinya; Sawada, Yasuhiko; Saikawa, Soichiro; Kitagawa, Koh; Takaya, Hiroaki; Kawaratani, Hideto; Kitade, Mitsuteru; Moriya, Kei; Noguchi, Ryuichi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
Jan-2008	Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and neovascularization.	Noguchi, Ryuichi; Yoshiji, Hitoshi; Ikenaka, Yasuhide; Kitade, Mitsuteru; Kaji, Kosuke; Yoshii, Junichi; Yanase, Koji; Namisaki, Tadashi; Yamazaki, Masaharu; Tsujimoto, Tatsuhiro; Akahane, Takemi; Uemura, Masahito; Fukui, Hiroshi
28-Dec-2021	Dual therapy with zinc acetate and rifaximin prevents from ethanolinduced liver fibrosis by maintaining intestinal barrier integrity	Fujimoto, Yuki; Kaji, Kosuke; Nishimura, Norihisa; Enomoto, Masahide; Murata, Koji; Takeda, Soichi; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
4-Aug-2020	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.	Fujinaga, Yukihisa; Kawaratani, Hideto; Kaya, Daisuke; Tsuji, Yuki; Ozutsumi, Takahiro; Furukawa, Masanori; Kitagawa, Koh; Sato, Shinya; Nishimura, Norihisa; Sawada, Yasuhiko; Takaya, Hiroaki; Kaji, Kosuke; Shimozato, Naotaka; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
Oct-2023	Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice	Iwai, Satoshi; Kaji, Kosuke; Nishimura, Norihisa; Kubo, Takahiro; Tomooka, Fumimasa; Shibamoto, Akihiko; Suzuki, Junya; Tsuji, Yuki; Fujinaga, Yukihisa; Kitagawa, Koh; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
Apr-2021	Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis.	Ogawa, Hiroyuki; Kaji, Kosuke; Nishimura, Norihisa; Takagi, Hirotetsu; Ishida, Koji; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
Oct-2022	Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet–induced rat steatohepatitis	Enomoto, Masahide; Kaji, Kosuke; Nishimura, Norihisa; Fujimoto, Yuki; Murata, Koji; Takeda, Soichi; Tsuji, Yuki; Fujinaga, Yukihisa; Tanaka, Hiroaki; Kawaratani, Hideto; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
Aug-2022	Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis	Murata, Koji; Kaji, Kosuke; Nishimura, Norihisa; Enomoto, Masahide; Fujimoto, Yuki; Takeda, Soichi; Tsuji, Yuki; Fujinaga, Yukihisa; Takaya, Hiroaki; Kawaratani, Hideto; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
Mar-2021	Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nrf2-mediated antioxidant response and acetaldehyde metabolization with inhibition of the LPS/TLR4 signaling pathway.	Ishida, Koji; Kaji, Kosuke; Sato, Shinya; Ogawa, Hiroyuki; Takagi, Hirotetsu; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
Dec-2018	Sulforaphane Inhibits Liver Cancer Cell Growth and Angiogenesis.	Sato, Shinya; Moriya, Kei; Furukawa, Masanori; Saikawa, Soichiro; Namisaki, Tadashi; Kitade, Mitsuteru; Kawaratani, Hideto; Kaji, Kosuke; Takaya, Hiroaki; Shimozato, Naotaka; Sawada, Yasuhiko; Seki, Kenichiro; Kitagawa, Kou; Akahane, Takemi; Mitoro, Akira; Okura, Yasushi; Yoshiji, Hitoshi; Yamao, Junichi
Feb-2023	Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity	Tomooka, Fumimasa; Kaji, Kosuke; Nishimura, Norihisa; Kubo, Takahiro; Iwai, Satoshi; Shibamoto, Akihiko; Suzuki, Junya; Kitagawa, Koh; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
26-Sep-2019	TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats.	Kaya, Daisuke; Kaji, Kosuke; Tsuji, Yuki; Yamashita, Satoko; Kitagawa, Koh; Ozutsumi, Takahiro; Fujinaga, Yukihisa; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
5-Mar-2021	The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects.	Takagi, Hirotetsu; Kaji, Kosuke; Nishimura, Norihisa; Ishida, Koji; Ogawa, Hiroyuki; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
Dec-2023	Vitamin D deficiency exacerbates alcohol-related liver injury via gut barrier disruption and hepatic overload of endotoxin	Shibamoto, Akihiko; Kaji, Kosuke; Nishimura, Norihisa; Kubo, Takahiro; Iwai, Satoshi; Tomooka, Fumimasa; Suzuki, Junya; Tsuji, Yuki; Fujinaga, Yukihisa; Kawaratani, Hideto; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi